Compare CAC & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CAC | ABUS |
|---|---|---|
| Founded | 1875 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 876.2M | 839.5M |
| IPO Year | 1996 | 2008 |
| Metric | CAC | ABUS |
|---|---|---|
| Price | $53.97 | $4.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $47.00 | $5.00 |
| AVG Volume (30 Days) | 101.7K | ★ 2.2M |
| Earning Date | 04-28-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.51% | N/A |
| EPS Growth | 6.08 | ★ 55.26 |
| EPS | ★ 1.29 | 0.87 |
| Revenue | ★ $41,739,000.00 | $14,083,000.00 |
| Revenue This Year | $19.15 | N/A |
| Revenue Next Year | $6.05 | $239.71 |
| P/E Ratio | $41.83 | ★ $5.38 |
| Revenue Growth | 16.96 | ★ 128.21 |
| 52 Week Low | $35.00 | $3.08 |
| 52 Week High | $54.79 | $5.10 |
| Indicator | CAC | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 66.69 | 66.90 |
| Support Level | $46.61 | $4.15 |
| Resistance Level | N/A | $4.85 |
| Average True Range (ATR) | 1.53 | 0.18 |
| MACD | 0.19 | 0.04 |
| Stochastic Oscillator | 85.06 | 91.98 |
Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.